Profile

Paul A. Carpenter, MD

Paul A. Carpenter, MD

"One of the most rewarding aspects of my work is the privilege of forging long-term relationships with families who are faced with what must be one of the most challenging experiences of their lives caring for a child with a life-threatening disorder that is potentially treatable by stem cell transplantation. When I see patients, I try to listen attentively and maintain open communication. I focus on empowering patients and their families with evidence-based knowledge and offering them treatment options that focus on quality of life."

Paul Carpenter, MBBS, is attending physician at Seattle Childrens Hospital and Fred Hutchinson Cancer Research Center (FHCRC) and professor at the University of Washington, with a focus on graft versus host disease (GVHD). He supervises junior attending staff on the pediatric hematopoietic cell transplant service at FHCRC. His local responsibilities include long-standing contributions to the FHCRC Standard Practice Committee and Standard Practice Manual.

He chairs a Data Safety Monitoring Board for multiple FHCRC protocols and serves on the FHCRC Scientific Review Committee and one of the two Institutional Review Boards. His clinical and research interests focus on GVHD, which is the major and potentially lethal complication of hematopoietic cell transplant. His research continues to explore new therapies for the treatment of acute and chronic GVHD, and he is an active member in the national efforts to advance the field of chronic GVHD treatment. He is studies therapies designed to ameliorate key morbidities associated with chronic immunosuppressive therapies, such as bisphosphonate therapy for glucocorticoid-induced bone disease and the use of statins to treat hyperlipidemia. He has designed and participated in studies to evaluate the safety and efficacy of tyrosine kinase inhibitors as post-transplant therapy for high-risk Philadelphia chromosomepositive leukemias and for the treatment of chronic graft versus host disease. He is currently a Principal Investigator of the inaugural Blood and Marrow Clinical Trials Network (BMT CTN) Phase II/III 0801 trial for chronic graft-versus-host-disease.

What's New

About This Site

Seattle Children’s provides healthcare without regard to race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry) or disability. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.